{"id":688615,"date":"2024-02-20T16:00:02","date_gmt":"2024-02-20T16:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=688615"},"modified":"2024-02-20T16:00:02","modified_gmt":"2024-02-20T16:00:02","slug":"venous-thromboembolism-market-to-witness-upsurge-in-growth-during-the-study-period-20192032-assesses-delveinsight-companies-verseon-quercis-ionis-bayer-bms-janssen-ono-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/venous-thromboembolism-market-to-witness-upsurge-in-growth-during-the-study-period-20192032-assesses-delveinsight-companies-verseon-quercis-ionis-bayer-bms-janssen-ono-pharma_688615.html","title":{"rendered":"Venous thromboembolism Market to Witness Upsurge in Growth During the Study Period (2019-2032), Assesses DelveInsight | Companies &#8211; Verseon, Quercis, Ionis, Bayer, BMS, Janssen, Ono Pharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1708409811.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Venous thromboembolism Market to Witness Upsurge in Growth During the Study Period (2019-2032), Assesses DelveInsight | Companies - Verseon, Quercis, Ionis, Bayer, BMS, Janssen, Ono Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1708409811.jpeg\" alt=\"Venous thromboembolism Market to Witness Upsurge in Growth During the Study Period (2019-2032), Assesses DelveInsight | Companies - Verseon, Quercis, Ionis, Bayer, BMS, Janssen, Ono Pharma\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Venous thromboembolism Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><em>As per DelveInsight, the Venous Thromboembolism market is expected to grow in the coming years owing to the expected launch of new therapies, extensive research and development (R&amp;D) activities of pharmaceutical companies, increased patient pool, improvement in the diagnosis rate owing to guidelines recommendations, and government initiatives.<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong>Venous Thromboembolism Market Insights, Epidemiology, and Market Forecast 2032<\/strong>&rdquo; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Venous Thromboembolism Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\">The Venous Thromboembolism market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Report @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/venous-thromboembolism-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Venous Thromboembolism Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Venous Thromboembolism: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>Venous Thromboembolism (VTE) is a disorder that includes Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) . A deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower leg, thigh, or pelvis. A deep vein thrombosis may occur if the flow of blood slows down in the body&rsquo;s deep veins. A pulmonary embolism (PE) occurs when a clot breaks loose and travels through the bloodstream to the lungs.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Venous Thromboembolism Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><em>As per the study by Ota et al., (2015), titled &ldquo;Incidence, Characteristics and Management of Venous Thromboembolism in Japan During 2011,&rdquo;, nearly&nbsp;<\/em><strong><em>16,096<\/em><\/strong><em>&nbsp;and&nbsp;<\/em><strong><em>24,538<\/em><\/strong><em>&nbsp;individuals in Japan were diagnosed with new PE and DVT, respectively, during 2011, which represented overall annual incidences of&nbsp;<\/em><strong><em>12.6<\/em><\/strong><em>&nbsp;and&nbsp;<\/em><strong><em>19.2 per 100,000,<\/em><\/strong><em>&nbsp; respectively.<\/em><\/li>\n<li><em>A multinational report of European Union countries estimated that the total number of symptomatic, nonfatal VTE events per annum was more than&nbsp;<\/em><strong><em>465,000 cases of DVT<\/em><\/strong><em>&nbsp;and more than&nbsp;<\/em><strong><em>295,000 cases of PE<\/em><\/strong><em>.&nbsp;<\/em><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Venous Thromboembolism Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted&nbsp;<strong>Venous Thromboembolism market size<\/strong>&nbsp;by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\">The report details the Venous Thromboembolism market trend for each marketed drug and late-stage pipeline therapy&nbsp;by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Venous Thromboembolism Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Venous Thromboembolism Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Incident Cases&nbsp;<\/li>\n<li>Total Diagnosed Cases&nbsp;<\/li>\n<li>Type-specific Cases&nbsp;<\/li>\n<li>Total Age-specific Cases&nbsp;<\/li>\n<li>Occurrence-specific Cases&nbsp;<\/li>\n<li>Total Prophylactic\/Preventive Setting Cases&nbsp;<\/li>\n<li>Total Potential (Mortality and Recurrent adjusted) Cases&nbsp;<\/li>\n<li>Total Treated Cases of VTE for Treatment and Prophylactic Settings<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Report @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/venous-thromboembolism-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Venous Thromboembolism Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Venous Thromboembolism Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the&nbsp;<strong>Venous Thromboembolism market<\/strong>&nbsp;or expected to get launched during the study period. The analysis covers Venous Thromboembolism market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the&nbsp;<strong>Venous Thromboembolism Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Venous Thromboembolism Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>The Venous Thromboembolism market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, and incremental healthcare spending worldwide.<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Companies in the Venous Thromboembolism Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Ionis Pharmaceuticals<\/li>\n<li>Bristol-Myers Squibb&nbsp;<\/li>\n<li>Janssen Pharmaceuticals<\/li>\n<li>Quercis Pharmaceuticals<\/li>\n<li>Ono Pharmaceutical<\/li>\n<li>Verseon Corporation<\/li>\n<li>Bayer Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And several others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Venous Thromboembolism Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>ONO-7684<\/li>\n<li>Milvexian<\/li>\n<li>Isoquercetin<\/li>\n<li>VE-1902<\/li>\n<li>IONIS-FXI-LRx<\/li>\n<li>Osocimab (BAY 1213790)&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &ndash;&nbsp; &nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\">3. Venous Thromboembolism Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\">4. Venous Thromboembolism Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Venous Thromboembolism Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Venous Thromboembolism Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Venous Thromboembolism Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Venous Thromboembolism Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Venous Thromboembolism Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Venous Thromboembolism Treatment<\/p>\n<p style=\"text-align: justify;\">11. Venous Thromboembolism Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Venous Thromboembolism Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Venous Thromboembolism Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\">15. Venous Thromboembolism Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\">16. Venous Thromboembolism Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\">17. KOL Views on the Venous Thromboembolism Market.<\/p>\n<p style=\"text-align: justify;\">18. Venous Thromboembolism Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Venous Thromboembolism Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=venous-thromboembolism-market-to-witness-upsurge-in-growth-during-the-study-period-20192032-assesses-delveinsight-companies-verseon-quercis-ionis-bayer-bms-janssen-ono-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91-9650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=venous-thromboembolism-market-to-witness-upsurge-in-growth-during-the-study-period-20192032-assesses-delveinsight-companies-verseon-quercis-ionis-bayer-bms-janssen-ono-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Venous thromboembolism Market As per DelveInsight, the Venous Thromboembolism market is expected to grow in the coming years owing to the expected launch of new therapies, extensive research and development (R&amp;D) activities of pharmaceutical companies, increased patient pool, improvement in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/venous-thromboembolism-market-to-witness-upsurge-in-growth-during-the-study-period-20192032-assesses-delveinsight-companies-verseon-quercis-ionis-bayer-bms-janssen-ono-pharma_688615.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-688615","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/688615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=688615"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/688615\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=688615"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=688615"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=688615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}